MedTrace Logo

Safety and TDM of Continuous Infusion Vancomycin Through Continuous Renal Replacement Therapy Solution

NCT02663596 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-10-19

No results posted yet for this study

Summary

The purpose of this investigation is to evaluate the safety of delivering continuous infusion (CI) vancomycin in pediatric CRRT by utilizing CI via by mixing the vancomycin into the CRRT solution(s). The secondary objectives are to describe the ability to achieve therapeutic vancomycin concentrations by utilizing this new delivery technique.

Primary Objectives:

To determine whether delivering continuous infusion vancomycin mixed into the CRRT solution can maintain therapeutic levels of drug in patients being treated for proven or suspected Gram-positive bacterial infections.

Conditions

  • Pediatric Continuous Renal Replacement Therapy
  • Dialysis
  • Renal Failure

Interventions

DRUG

Vancomycin

Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)

Sponsors & Collaborators

  • The Center for Pediatric Pharmacotherapy, LLC

    collaborator UNKNOWN

  • Drexel University

    lead OTHER

Principal Investigators

  • Jeffrey J Cies, PharmD, MPH · Drexel University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02663596 on ClinicalTrials.gov